Quantum Cyber N.V.

QUCY

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001874252

None

No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $5.3M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	thin data not computable: dilution, short runway, distress, fortress balance sheet
Inputs computable	3 of 14
Graded from	filings received through Mar 31, 2026 227 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026
Last close	$0.56 2026-11-12; market equity $49.2M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

Historically, we have developed and sold in-vitro diagnostic ("IVD") tests for the early detection of cancer. In March 2025, we acquired a license from Liquid Bioscience, Inc. to access a portfolio of novel mRNA biomarkers and AI developed proprietary algorithm, for the non-invasive detection of pancreatic cancer with a blood test. We have an exclusive license to develop such a test using these biomarkers and algorithm with the unilateral option to acquire them. We are also developing a product candidate called PancAlert, a stool-based screening test aimed at detecting pancreatic cancer.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 80.2						
Gross profitability	7.3%	32.3%		80.2	365	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	not computable	(6.6%)			
a prior annual assets observation is required					
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 1					
Solvency, sleeve percentile 94.3					
Twelve-month failure probability	not computable	0.08%			
four consecutive discrete net-income quarters are required; found 3					
Altman Z double-prime	(86.69)	(0.35)	93.5	744	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	0.50x	2.95x	95.0	826	2025-12-31
Growth and financing					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 1					
Free cash flow growth, three-year compound	not computable	11.0%			
four consecutive annual FCF observations are required; found 1					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	not computable	2.2%			
four annual observations are required; found 1					
Net share issuance, one year	not computable	2.5%			
two annual share counts are required; found 1					

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	3 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-12 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(11.5%)	(1.9%)	43
Distance from 52-week high	(84.1%)	(30.8%)	7
EBIT to enterprise value	not computable	(1.9%)	
Free cash flow yield	(22.3%)	(1.0%)	23
Book value to price	0.33	0.28	55
Sales to price	0.01	0.29	6
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.29)	(0.19)	43

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	1 (10-Q received Nov 12, 2026)
Median daily dollar volume, 63 sessions	$485,123

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$389,792	2025-12-31	2026-03-31	10-K	26-037676
2	assets	us-gaap:Assets	$5.3M	2025-12-31	2026-03-31	10-K	26-037676
3	net income	us-gaap:NetIncomeLoss	-$16.2M	2025-12-31	2026-03-31	10-K	26-037676
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$11.0M	2025-12-31	2026-03-31	10-K	26-037676
5	current assets	us-gaap:AssetsCurrent	$1.8M	2025-12-31	2026-03-31	10-K	26-037676
6	current liabilities	us-gaap:LiabilitiesCurrent	$3.7M	2025-12-31	2026-03-31	10-K	26-037676
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$104.9M	2025-12-31	2026-03-31	10-K	26-037676
8	operating income	us-gaap:OperatingIncomeLoss	-$16.1M	2025-12-31	2026-03-31	10-K	26-037676
9	book equity	us-gaap:StockholdersEquity	$641,600	2025-12-31	2026-03-31	10-K	26-037676
10	liabilities	us-gaap:Liabilities	$4.7M	2025-12-31	2026-03-31	10-K	26-037676
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$537,080	2025-12-31	2026-03-31	10-K	26-037676
12	shares outstanding	dei:EntityCommonStockSharesOutstanding	12,515,336	2026-03-30	2026-03-31	10-K	26-037676

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.